Terms: = Lymphoma AND SYK, P43405, 6850, ENSG00000165025 AND Treatment
100 results:
1. [Research Progress of Targeted Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic lymphoma --Review].
Chen D; Wang MY; Tian C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
[TBL] [Abstract] [Full Text] [Related]
2. Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available syk Inhibitor.
Cai Y; He J; Wu Z; He W; Dai X; Xu Y; Cheng M; Yang N; Ren Y; Wang G; Wang J; Sai Y; Jia H; Dai G; Li X; Su W
J Pharmacol Exp Ther; 2024 Jan; 388(1):156-170. PubMed ID: 37918855
[TBL] [Abstract] [Full Text] [Related]
3. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).
Gordon LI; Karmali R; Kaplan JB; Popat R; Burris HA; Ferrari S; Madan S; Patel MR; Gritti G; El-Sharkawi D; Chau FI; Radford J; de Oteyza JP; Zinzani PL; Iyer SP; Townsend W; Miao H; Proscurshim I; Wang S; Katyayan S; Yuan Y; Zhu J; Stumpo K; Shou Y; Carpio C; Bosch F
Oncotarget; 2023 Jan; 14():57-70. PubMed ID: 36702329
[TBL] [Abstract] [Full Text] [Related]
4. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms.
Jaeger A; Gambheer SMM; Sun X; Chernyakov D; Skorobohatko O; Mack T; Kissel S; Pfeifer D; Zeiser R; Fisch P; Andrieux G; Bräuer-Hartmann D; Bauer M; Schulze S; Follo M; Boerries M; von Bubnoff N; Miething C; Hidalgo JV; Klein C; Weber T; Wickenhauser C; Binder M; Dierks C
Blood; 2023 Jun; 141(23):2824-2840. PubMed ID: 36696631
[TBL] [Abstract] [Full Text] [Related]
5. Recent advances in understanding spleen tyrosine kinase (syk) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract] [Full Text] [Related]
6. Population Pharmacokinetics of Mivavotinib (TAK-659), a Dual Spleen Tyrosine Kinase and FMS-Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic Malignancies.
Li C; Watson K; Wang S; Diderichsen PM; Gupta N
J Clin Pharmacol; 2023 Mar; 63(3):326-337. PubMed ID: 36309821
[TBL] [Abstract] [Full Text] [Related]
7. Dual BTK/syk inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
Thieme E; Liu T; Bruss N; Roleder C; Lam V; Wang X; Nechiporuk T; Shouse G; Danilova OV; Bottomly D; McWeeney SK; Tyner JW; Kurtz SE; Danilov AV
Cell Death Dis; 2022 Mar; 13(3):246. PubMed ID: 35296646
[TBL] [Abstract] [Full Text] [Related]
8. A new role for the SRC family kinase HCK as a driver of syk activation in MYD88 mutated lymphomas.
Munshi M; Liu X; Kofides A; Tsakmaklis N; Guerrera ML; Hunter ZR; Palomba ML; Argyropoulos KV; Patterson CJ; Canning AG; Meid K; Gustine J; Branagan AR; Flynn CA; Sarosiek S; Castillo JJ; Wang J; Buhrlage SJ; Gray NS; Munshi NC; Anderson KC; Treon SP; Yang G
Blood Adv; 2022 Jun; 6(11):3332-3338. PubMed ID: 35255496
[TBL] [Abstract] [Full Text] [Related]
9. Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell lymphoma.
Devin J; Cañeque T; Lin YL; Mondoulet L; Veyrune JL; Abouladze M; Garcia De Paco E; Karmous Gadacha O; Cartron G; Pasero P; Bret C; Rodriguez R; Moreaux J
Cancer Res; 2022 Mar; 82(6):998-1012. PubMed ID: 35078814
[TBL] [Abstract] [Full Text] [Related]
10. DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.
Chang S; Li B; Xie Y; Wang Y; Xu Z; Jin S; Yu D; Wang H; Lu Y; Zhang Y; Ma R; Huang C; Lai W; Wu X; Zhu W; Shi J
Neoplasia; 2022 Jan; 24(1):50-61. PubMed ID: 34890905
[TBL] [Abstract] [Full Text] [Related]
11. Influence of Vincristine, Clinically Used in Cancer Therapy and Immune Thrombocytopenia, on the Function of Human Platelets.
Lien LM; Lu WJ; Lin KH; Kang LH; Chen TY; Lin BJ; Lu YC; Huang CY; Shih CM; Chen H; Tsai YC; Chen RJ; Sheu JR
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500771
[TBL] [Abstract] [Full Text] [Related]
12. Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.
Elias EE; Sarapura Martinez VJ; Amondarain M; Colado A; Cordini G; Bezares RF; Fernandez Grecco H; Custidiano MDR; Sánchez Ávalos JC; Garate G; Pavlovsky MA; Borge M; Giordano M; Gamberale R
Cancer Immunol Immunother; 2022 Apr; 71(4):979-987. PubMed ID: 34467417
[TBL] [Abstract] [Full Text] [Related]
13. Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.
Thomas KR; Allenspach EJ; Camp ND; Wray-Dutra MN; Khim S; Zielinska-Kwiatkowska A; Timms AE; Loftus JP; Liggitt HD; Georgopoulos K; Tasian SK; James RG; Rawlings DJ
Leukemia; 2022 Jan; 36(1):42-57. PubMed ID: 34193976
[TBL] [Abstract] [Full Text] [Related]
14. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE; Burger JA
Front Immunol; 2021; 12():689472. PubMed ID: 34177947
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic and predictive value of a mRNA signature in peripheral T-cell lymphomas: A mRNA expression analysis.
Tu J; Kuang Z; Xie X; Wu S; Wu T; Chen S
J Cell Mol Med; 2021 Jan; 25(1):84-95. PubMed ID: 33259129
[TBL] [Abstract] [Full Text] [Related]
16. A novel somatic PLCG2 variant associated with resistance to BTK and syk inhibition in chronic lymphocytic leukemia.
Raghunathan V; Fan G; Kittai AS; Okada C; Danilov AV; Spurgeon SE
Eur J Haematol; 2021 Feb; 106(2):294-297. PubMed ID: 33089525
[TBL] [Abstract] [Full Text] [Related]
17. Phase I Study of TAK-659, an Investigational, Dual syk/FLT3 Inhibitor, in Patients with B-Cell lymphoma.
Gordon LI; Kaplan JB; Popat R; Burris HA; Ferrari S; Madan S; Patel MR; Gritti G; El-Sharkawi D; Chau I; Radford JA; Pérez de Oteyza J; Zinzani PL; Iyer S; Townsend W; Karmali R; Miao H; Proscurshim I; Wang S; Wu Y; Stumpo K; Shou Y; Carpio C; Bosch F
Clin Cancer Res; 2020 Jul; 26(14):3546-3556. PubMed ID: 32327472
[TBL] [Abstract] [Full Text] [Related]
18. Diffuse large B-cell lymphoma with low
Sheng D; Li T; Wang WG; Li MJ; Jiang KL; Gao AH; Li J; Zhou XY; Li XQ
Leuk Lymphoma; 2020 Jun; 61(6):1364-1371. PubMed ID: 32090646
[TBL] [Abstract] [Full Text] [Related]
19. Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
Lemm EA; Valle-Argos B; Smith LD; Richter J; Gebreselassie Y; Carter MJ; Karolova J; Svaton M; Helman K; Weston-Bell NJ; Karydis L; Williamson CT; Lenz G; Pettigrew J; Harwig C; Stevenson FK; Cragg M; Forconi F; Steele AJ; Cross J; Mackenzie L; Klener P; Packham G
Clin Cancer Res; 2020 Apr; 26(7):1700-1711. PubMed ID: 31831562
[TBL] [Abstract] [Full Text] [Related]
20. syk Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
Serafin V; Porcù E; Cortese G; Mariotto E; Veltri G; Bresolin S; Basso G; Accordi B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817853
[TBL] [Abstract] [Full Text] [Related]
[Next]
